<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00706134</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100A2405</org_study_id>
    <nct_id>NCT00706134</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study</brief_title>
  <official_title>An Eight-week Double-blind, Multi-center, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in
      elderly patients with essential hypertension when given with a light meal.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Sitting Systolic Blood Pressure (msSBP)From Baseline to End of Study (Week 8)</measure>
    <time_frame>Baseline to end of study (Week 8)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)</measure>
    <time_frame>Baseline to end of study (Week 8)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Systolic Blood Pressure Response</measure>
    <time_frame>Baseline to end of study (Week 8)</time_frame>
    <description>Patients achieving a systolic blood pressure response had to have a msSBP &lt; 140 mmHg at the end of the study and/or a ≥ 20 mmHg reduction in msSBP from baseline to the end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean 24 Hour Ambulatory Systolic and Diastolic Blood Pressure From Baseline to End of Study</measure>
    <time_frame>Baseline to end of study (Week 8)</time_frame>
    <description>Two 24-hour ambulatory blood pressure monitoring (ABPM) evaluations were performed, one at baseline and one at the end of the study. For each evaluation, the ABPM device was attached to the non-dominant arm of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Smoothness Index (SI) of the Ambulatory Systolic Blood Pressure From Baseline to End of Study (Week 8)</measure>
    <time_frame>Baseline to end of study (Week 8)</time_frame>
    <description>Smoothness index (SI) is a measure of consistency of the BP reduction over 24 hours. The SI was obtained by first calculating the mean blood pressure value at each hour of the 24-hour ambulatory blood pressure monitoring period, both before and during treatment. Similarly, the change from baseline in blood pressure was calculated at each hour. The average hourly change from baseline (δh) and standard deviation (std δh) of the hourly changes were computed, and the SI was derived: SI = δh/std δh. A negative change score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Morning Surge of Ambulatory Systolic Blood Pressure From Baseline to End of Study (Week 8)</measure>
    <time_frame>Baseline to end of study (week 8)</time_frame>
    <description>The morning surge was defined as the average of the hourly means in the last three hours (hours 22, 23, 24) of the 24 hour ambulatory blood pressure monitoring assessment period.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">756</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet taken once daily in the morning with a light meal.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren 75 mg</intervention_name>
    <description>Aliskiren 75 mg tablet taken once daily in the morning with a light meal.</description>
    <arm_group_label>Aliskiren 75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren 150 mg</intervention_name>
    <description>Aliskiren 150 mg tablet taken once daily in the morning with a light meal.</description>
    <arm_group_label>Aliskiren 150 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren 300 mg</intervention_name>
    <description>Aliskiren 300 mg tablet taken once daily in the morning with a light meal.</description>
    <arm_group_label>Aliskiren 300 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female outpatients 65 years of age and older.

          -  Patients who are eligible and able to participate in the study, and who consent to do
             so after the purpose and nature of the investigation has been clearly explained to
             them (written informed consent).

          -  At the randomization visit patients must have an office msSBP greater than or equal to
             150 mmHg and &lt; 180 mmHg (msDBP &lt;110 mmHg) with a less than or equal to 15 mmHg
             difference during the last two visits of the single blind run-in period.

        Exclusion Criteria:

          -  Severe hypertension [Office msDBP ≥110 mmHg and/or mean sitting systolic blood
             pressure (msSBP) ≥ 180 mmHg].

          -  History or evidence of a secondary form of hypertension.

          -  Known Keith-Wagener grade III or IV hypertensive retinopathy.

          -  History of hypertensive encephalopathy or cerebrovascular accident, including a
             history of transient ischemic cerebral attack (TIA).

          -  Current diagnosis of heart failure (NYHA Class II-IV).

          -  History of myocardial infarction, coronary bypass surgery, or any percutaneous
             coronary intervention (PCI).

          -  Current angina pectoris requiring pharmacological therapy other than nitrates.

        Other protocol-defined inclusion/exclusion criteria applied to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Reykjavik</city>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Iceland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Slovakia</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2008</study_first_submitted>
  <study_first_submitted_qc>June 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2008</study_first_posted>
  <results_first_submitted>January 10, 2011</results_first_submitted>
  <results_first_submitted_qc>May 18, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2011</results_first_posted>
  <last_update_submitted>June 24, 2011</last_update_submitted>
  <last_update_submitted_qc>June 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Novartis</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>≥ 65 years</keyword>
  <keyword>aliskiren</keyword>
  <keyword>placebo</keyword>
  <keyword>light meal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo tablet taken once daily in the morning with a light meal.</description>
        </group>
        <group group_id="P2">
          <title>Aliskiren 75 mg</title>
          <description>Aliskiren 75 mg tablet taken once daily in the morning with a light meal.</description>
        </group>
        <group group_id="P3">
          <title>Aliskiren 150 mg</title>
          <description>Aliskiren 150 mg tablet taken once daily in the morning with a light meal.</description>
        </group>
        <group group_id="P4">
          <title>Aliskiren 300 mg</title>
          <description>Aliskiren 300 mg tablet taken once daily in the morning with a light meal.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="192"/>
                <participants group_id="P3" count="189"/>
                <participants group_id="P4" count="186"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered Double-blind Period</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="192"/>
                <participants group_id="P3" count="189"/>
                <participants group_id="P4" count="186"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="173"/>
                <participants group_id="P3" count="183"/>
                <participants group_id="P4" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet study criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo tablet taken once daily in the morning with a light meal.</description>
        </group>
        <group group_id="B2">
          <title>Aliskiren 75 mg</title>
          <description>Aliskiren 75 mg tablet taken once daily in the morning with a light meal.</description>
        </group>
        <group group_id="B3">
          <title>Aliskiren 150 mg</title>
          <description>Aliskiren 150 mg tablet taken once daily in the morning with a light meal.</description>
        </group>
        <group group_id="B4">
          <title>Aliskiren 300 mg</title>
          <description>Aliskiren 300 mg tablet taken once daily in the morning with a light meal.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="189"/>
            <count group_id="B2" value="192"/>
            <count group_id="B3" value="189"/>
            <count group_id="B4" value="186"/>
            <count group_id="B5" value="756"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≥ 65 and &lt; 75 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="129"/>
                    <measurement group_id="B5" value="517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 75 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="102"/>
                    <measurement group_id="B5" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="84"/>
                    <measurement group_id="B5" value="339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Sitting Systolic Blood Pressure (msSBP)From Baseline to End of Study (Week 8)</title>
        <time_frame>Baseline to end of study (Week 8)</time_frame>
        <population>Full analysis set (FAS) - All randomized patients. Two randomized patients who did not meet study criteria were excluded from the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet taken once daily in the morning with a light meal.</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren 75 mg</title>
            <description>Aliskiren 75 mg tablet taken once daily in the morning with a light meal.</description>
          </group>
          <group group_id="O3">
            <title>Aliskiren 150 mg</title>
            <description>Aliskiren 150 mg tablet taken once daily in the morning with a light meal.</description>
          </group>
          <group group_id="O4">
            <title>Aliskiren 300 mg</title>
            <description>Aliskiren 300 mg tablet taken once daily in the morning with a light meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Sitting Systolic Blood Pressure (msSBP)From Baseline to End of Study (Week 8)</title>
          <population>Full analysis set (FAS) - All randomized patients. Two randomized patients who did not meet study criteria were excluded from the FAS.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="192"/>
                <count group_id="O3" value="188"/>
                <count group_id="O4" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.97" spread="1.043"/>
                    <measurement group_id="O2" value="-12.51" spread="1.024"/>
                    <measurement group_id="O3" value="-15.28" spread="1.035"/>
                    <measurement group_id="O4" value="-14.14" spread="1.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)</title>
        <time_frame>Baseline to end of study (Week 8)</time_frame>
        <population>Full analysis set (FAS) - All randomized patients. Two randomized patients who did not meet study criteria were excluded from the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet taken once daily in the morning with a light meal.</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren 75 mg</title>
            <description>Aliskiren 75 mg tablet taken once daily in the morning with a light meal.</description>
          </group>
          <group group_id="O3">
            <title>Aliskiren 150 mg</title>
            <description>Aliskiren 150 mg tablet taken once daily in the morning with a light meal.</description>
          </group>
          <group group_id="O4">
            <title>Aliskiren 300 mg</title>
            <description>Aliskiren 300 mg tablet taken once daily in the morning with a light meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)</title>
          <population>Full analysis set (FAS) - All randomized patients. Two randomized patients who did not meet study criteria were excluded from the FAS.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="192"/>
                <count group_id="O3" value="188"/>
                <count group_id="O4" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.50" spread="0.579"/>
                    <measurement group_id="O2" value="-5.33" spread="0.568"/>
                    <measurement group_id="O3" value="-6.42" spread="0.575"/>
                    <measurement group_id="O4" value="-6.66" spread="0.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Systolic Blood Pressure Response</title>
        <description>Patients achieving a systolic blood pressure response had to have a msSBP &lt; 140 mmHg at the end of the study and/or a ≥ 20 mmHg reduction in msSBP from baseline to the end of the study.</description>
        <time_frame>Baseline to end of study (Week 8)</time_frame>
        <population>Full analysis set (FAS) - All randomized patients. Two randomized patients who did not meet study criteria were excluded from the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet taken once daily in the morning with a light meal.</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren 75 mg</title>
            <description>Aliskiren 75 mg tablet taken once daily in the morning with a light meal.</description>
          </group>
          <group group_id="O3">
            <title>Aliskiren 150 mg</title>
            <description>Aliskiren 150 mg tablet taken once daily in the morning with a light meal.</description>
          </group>
          <group group_id="O4">
            <title>Aliskiren 300 mg</title>
            <description>Aliskiren 300 mg tablet taken once daily in the morning with a light meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Systolic Blood Pressure Response</title>
          <description>Patients achieving a systolic blood pressure response had to have a msSBP &lt; 140 mmHg at the end of the study and/or a ≥ 20 mmHg reduction in msSBP from baseline to the end of the study.</description>
          <population>Full analysis set (FAS) - All randomized patients. Two randomized patients who did not meet study criteria were excluded from the FAS.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="192"/>
                <count group_id="O3" value="188"/>
                <count group_id="O4" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8"/>
                    <measurement group_id="O2" value="42.4"/>
                    <measurement group_id="O3" value="44.1"/>
                    <measurement group_id="O4" value="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean 24 Hour Ambulatory Systolic and Diastolic Blood Pressure From Baseline to End of Study</title>
        <description>Two 24-hour ambulatory blood pressure monitoring (ABPM) evaluations were performed, one at baseline and one at the end of the study. For each evaluation, the ABPM device was attached to the non-dominant arm of the patient.</description>
        <time_frame>Baseline to end of study (Week 8)</time_frame>
        <population>Ambulatory blood pressure monitoring completers population: All patients that completed both ambulatory blood pressure monitoring assessments successfully.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet taken once daily in the morning with a light meal.</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren 75 mg</title>
            <description>Aliskiren 75 mg tablet taken once daily in the morning with a light meal.</description>
          </group>
          <group group_id="O3">
            <title>Aliskiren 150 mg</title>
            <description>Aliskiren 150 mg tablet taken once daily in the morning with a light meal.</description>
          </group>
          <group group_id="O4">
            <title>Aliskiren 300 mg</title>
            <description>Aliskiren 300 mg tablet taken once daily in the morning with a light meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean 24 Hour Ambulatory Systolic and Diastolic Blood Pressure From Baseline to End of Study</title>
          <description>Two 24-hour ambulatory blood pressure monitoring (ABPM) evaluations were performed, one at baseline and one at the end of the study. For each evaluation, the ABPM device was attached to the non-dominant arm of the patient.</description>
          <population>Ambulatory blood pressure monitoring completers population: All patients that completed both ambulatory blood pressure monitoring assessments successfully.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambulatory Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" spread="1.280"/>
                    <measurement group_id="O2" value="-3.33" spread="1.155"/>
                    <measurement group_id="O3" value="-5.76" spread="1.128"/>
                    <measurement group_id="O4" value="-5.83" spread="1.520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ambulatory Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.990"/>
                    <measurement group_id="O2" value="-1.78" spread="0.877"/>
                    <measurement group_id="O3" value="-3.26" spread="0.693"/>
                    <measurement group_id="O4" value="-2.45" spread="0.823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Smoothness Index (SI) of the Ambulatory Systolic Blood Pressure From Baseline to End of Study (Week 8)</title>
        <description>Smoothness index (SI) is a measure of consistency of the BP reduction over 24 hours. The SI was obtained by first calculating the mean blood pressure value at each hour of the 24-hour ambulatory blood pressure monitoring period, both before and during treatment. Similarly, the change from baseline in blood pressure was calculated at each hour. The average hourly change from baseline (δh) and standard deviation (std δh) of the hourly changes were computed, and the SI was derived: SI = δh/std δh. A negative change score indicates improvement.</description>
        <time_frame>Baseline to end of study (Week 8)</time_frame>
        <population>Ambulatory blood pressure monitoring completers population: All patients that completed both ambulatory blood pressure monitoring assessments successfully.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet taken once daily in the morning with a light meal.</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren 75 mg</title>
            <description>Aliskiren 75 mg tablet taken once daily in the morning with a light meal.</description>
          </group>
          <group group_id="O3">
            <title>Aliskiren 150 mg</title>
            <description>Aliskiren 150 mg tablet taken once daily in the morning with a light meal.</description>
          </group>
          <group group_id="O4">
            <title>Aliskiren 300 mg</title>
            <description>Aliskiren 300 mg tablet taken once daily in the morning with a light meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Smoothness Index (SI) of the Ambulatory Systolic Blood Pressure From Baseline to End of Study (Week 8)</title>
          <description>Smoothness index (SI) is a measure of consistency of the BP reduction over 24 hours. The SI was obtained by first calculating the mean blood pressure value at each hour of the 24-hour ambulatory blood pressure monitoring period, both before and during treatment. Similarly, the change from baseline in blood pressure was calculated at each hour. The average hourly change from baseline (δh) and standard deviation (std δh) of the hourly changes were computed, and the SI was derived: SI = δh/std δh. A negative change score indicates improvement.</description>
          <population>Ambulatory blood pressure monitoring completers population: All patients that completed both ambulatory blood pressure monitoring assessments successfully.</population>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.102"/>
                    <measurement group_id="O2" value="-0.38" spread="0.092"/>
                    <measurement group_id="O3" value="-0.50" spread="0.089"/>
                    <measurement group_id="O4" value="-0.51" spread="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Morning Surge of Ambulatory Systolic Blood Pressure From Baseline to End of Study (Week 8)</title>
        <description>The morning surge was defined as the average of the hourly means in the last three hours (hours 22, 23, 24) of the 24 hour ambulatory blood pressure monitoring assessment period.</description>
        <time_frame>Baseline to end of study (week 8)</time_frame>
        <population>Ambulatory blood pressure monitoring completers population: All patients that completed both ambulatory blood pressure monitoring assessments successfully.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet taken once daily in the morning with a light meal.</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren 75 mg</title>
            <description>Aliskiren 75 mg tablet taken once daily in the morning with a light meal.</description>
          </group>
          <group group_id="O3">
            <title>Aliskiren 150 mg</title>
            <description>Aliskiren 150 mg tablet taken once daily in the morning with a light meal.</description>
          </group>
          <group group_id="O4">
            <title>Aliskiren 300 mg</title>
            <description>Aliskiren 300 mg tablet taken once daily in the morning with a light meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Morning Surge of Ambulatory Systolic Blood Pressure From Baseline to End of Study (Week 8)</title>
          <description>The morning surge was defined as the average of the hourly means in the last three hours (hours 22, 23, 24) of the 24 hour ambulatory blood pressure monitoring assessment period.</description>
          <population>Ambulatory blood pressure monitoring completers population: All patients that completed both ambulatory blood pressure monitoring assessments successfully.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="1.782"/>
                    <measurement group_id="O2" value="-3.04" spread="1.596"/>
                    <measurement group_id="O3" value="-7.03" spread="1.539"/>
                    <measurement group_id="O4" value="-3.96" spread="1.660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>End of study (week 8)</time_frame>
      <desc>Population description of safety set.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo tablet taken once daily in the morning with a light meal.</description>
        </group>
        <group group_id="E2">
          <title>Aliskiren 75 mg</title>
          <description>Aliskiren 75 mg tablet taken once daily in the morning with a light meal.</description>
        </group>
        <group group_id="E3">
          <title>Aliskiren 150 mg</title>
          <description>Aliskiren 150 mg tablet taken once daily in the morning with a light meal.</description>
        </group>
        <group group_id="E4">
          <title>Aliskiren 300 mg</title>
          <description>Aliskiren 300 mg tablet taken once daily in the morning with a light meal.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

